Overall verdict
Sell
2.9/10
1-year performance
-46.61%
Score breakdown
Down 46.6% over 1 year, 0% of the 52-week range.
Strongest: Growth 8.4/10. Weakest: Shareholder return 0.0/10.
ROKIT Healthcare Inc., a biotechnology company, provides hyper-personalized organ regenerative healthcare solutions in South Korea. The company offers skin regeneration therapy for the treatment of diabetic foot ulcers; cartilage regeneration delivers hyper-personalized therapeutic solutions for osteoarthritis patients; and kidney regeneration, a hyper-personalized treatment for chronic kidney disease (CKD).
It also provides bioprinters; bioinks; Huma Media, a human adult stem cell culture media; HumaTein, a human cell-derived whole extracellular matrix; EpiTem, a reconstructed human epidermis model; and anti-aging supplements, as well as operates a tissue bank. The company was formerly known as ROKIT Inc. and changed its name to ROKIT Healthcare Inc. in 2018. The company was incorporated in 2012 and is based in Seoul, South Korea.
Sector
Health Care
Industry
Biotechnology
Primary listing
Krx
South Korea
CEO
Seok-hwan Yoo
Founded
2012
Employees
90
Revenue / employee
292M KRW
Next earnings
—
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
153800.00 KRW
52-week low
18020.00 KRW
1-year performance
-46.61%
Declining
Year-to-date performance
-72.70%
Declining
Drawdown
-88.28%
Major drawdown
Position in the 52-week range
0% of range
Gross margin 46.8%, the company loses 38.7% of its revenue, ROIC -161.2%, ROE -166.4%.
Net margin
-38.67%
Negative
Sector -224.99%|S&P 13.15%
Gross margin
46.79%
High
Return on equity (ROE)
-166.42%
Negative
Sector -58.62%|S&P 16.61%
Return on invested capital (ROIC)
-161.19%
Negative
Free cash flow margin (FCF)
-79.79%
Negative
Growth
8.4/10Revenue up 36.6% over 1 year.
Revenue (trailing 12 months)
30.5Md KRW
Revenue growth (1y)
36.64%
Strong
Revenue growth (3y)
186.82%
Hyper-growth
EPS growth (1y)
—
EPS CAGR (5y)
—
EPS revisions (3 months)
—
Valuation
1.3/10The company loses money, so no valuation multiple can be read: a negative P/E is not a discount.
P/E (TTM)
—
N/A (loss)
Sector 11.4x|S&P 24.1x
Forward P/E (adjusted)
30.6x
Expensive
EV / EBITDA
—
N/A (loss)
Sector 14.4x|S&P 15.2x
PEG
—
Sector -0.03|S&P 0.90
Market cap
389Md KRW
Financial strength
7.5/10Cash covers 126.9% of the debt, net debt/EBITDA -7.1x.
Net debt / EBITDA
-7.1x
Net cash
Gearing (net debt / equity)
-199.20%
Net cash
Cash
58.8Md KRW
Cash / market cap
15.11%
Very solid
Cash / total debt
126.90%
Net cash
Interest coverage
-3.2x
Stretched
Net debt
-12.5Md KRW
Equity
6.3Md KRW
Closed daily candles, 17 months
Last close on October 21, 2026: 22,400.00 KRW
- MM2025,730.00
- MM5027,801.00
- MM20058,715.50
- RSI 1438.8
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
-7.90%
200-day average slope, 3 months
-8.30%
50-day average slope, 1 month
-18.68%
Price structure
Lower lows
Bullish RSI divergence
No
20-day volatility
4.82 % per day
Volatility change
-36.29%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | — | 546.00 | 40 000 | — | — |
Amounts in millions of KRW, EPS in KRW per share. In brackets, the number of analysts. Consensus as of October 21, 2025.
Same sub-industry: 781 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | AGEN | 5.6 | 4.9 | 289M USD | 2.4x | 69.3 % | 34.4 % | -11.7 % | 6.7x | -34.1 % | 44.8 % | ||
| 2 | SRZN | 5.5 | 4.3 | 298M USD | Not meaningful (loss) | -3042.9 % | 408.6 % | — | 2.2x | -11.8 % | 87.6 % | ||
| 3 | 6915 | 4.9 | 4.9 | 285M USD | — | — | 6.7 % | — | -0.7x | — | -7.8 % | ||
| 4 | PRLD | 4.7 | 3.5 | 291M USD | Not meaningful (loss) | -269.7 % | 73.4 % | -50.5 % | 2.0x | -11.4 % | 182.9 % | ||
| 5 | BNTC | 4.4 | N/A | 297M USD | Not meaningful (loss) | — | — | -33.1 % | 3.5x | -5.9 % | -46.2 % | ||
| 6 | NWBO | 3.5 | 4.0 | 281M USD | Not meaningful (loss) | -1736.4 % | 535.4 % | 275.6 % | -1.3x | -17.7 % | -25.0 % | ||
| 7 | IPSC | 3.4 | 1.5 | 292M USD | Not meaningful (loss) | -100.6 % | 1556.8 % | -41.9 % | 0.9x | -30.2 % | 182.2 % | ||
| 8 | XFOR | 3.2 | 3.0 | 298M USD | Not meaningful (loss) | -568.8 % | 346.3 % | -57.6 % | 1.5x | — | -4.4 % | ||
| 9 | A376900 | 2.9 | 3.2 | 293M USD | Not meaningful (loss) | -38.7 % | 36.6 % | -161.2 % | -7.1x | -6.3 % | -46.6 % |
